Sean Mackay's most recent trade in Standard BioTools Inc was a trade of 500,000 Common Stock done . Disclosure was reported to the exchange on June 20, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Standard BioTools Inc | Sean Mackay | SVP & Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2026 | 500,000 | 1,506,552 (2%) | 0% | 0 | Common Stock | |
| Standard BioTools Inc | Sean Mackay | SVP & Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.00 per share. | 20 May 2026 | 25,729 | 1,006,552 (1%) | 0% | 1 | 25,729 | Common Stock |
| Standard BioTools Inc | Sean Mackay | SVP & Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2026 | 612,240 | 612,240 | - | - | Stock Option (Right to buy) | |
| Standard BioTools Inc | Sean Mackay | SVP & Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2026 | 272,107 | 1,032,281 (1%) | 0% | 0 | Common Stock | |
| Standard BioTools Inc | Sean Mackay | SVP & Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.15 per share. | 23 Feb 2026 | 19,661 | 760,174 (1%) | 0% | 1.1 | 22,610 | Common Stock |
| Standard BioTools Inc | Sean Mackay | SVP & Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.28 per share. | 20 Nov 2025 | 19,661 | 779,835 (1%) | 0% | 1.3 | 25,166 | Common Stock |
| Standard BioTools Inc | Sean Mackay | SVP & Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.27 per share. | 20 Aug 2025 | 19,661 | 799,496 (1%) | 0% | 1.3 | 24,969 | Common Stock |
| Standard BioTools Inc | Sean Mackay | SVP & Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.09 per share. | 28 May 2025 | 23,919 | 819,157 (1%) | 0% | 1.1 | 26,072 | Common Stock |
| Standard BioTools Inc | Sean Mackay | SVP & Chief Business Officer | Sale of securities on an exchange or to another person at price $ 0.94 per share. | 23 May 2025 | 13,217 | 843,076 (1%) | 0% | 0.9 | 12,437 | Common Stock |
| Standard BioTools Inc | Sean Mackay | SVP & Chief Business Officer | Sale of securities on an exchange or to another person at price $ 1.03 per share. | 21 May 2025 | 12,838 | 868,829 (1%) | 0% | 1.0 | 13,223 | Common Stock |
| Standard BioTools Inc | Sean Mackay | SVP & Chief Business Officer | Sale of securities on an exchange or to another person at price $ 1.00 per share. | 21 May 2025 | 12,536 | 856,293 (1%) | 0% | 1.0 | 12,561 | Common Stock |
| Standard BioTools Inc | Sean Mackay | SVP & Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2025 | 422,500 | 422,500 | - | - | Stock Option (Right to Buy) | |
| Standard BioTools Inc | Sean Mackay | SVP & Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2025 | 281,667 | 881,667 (1%) | 0% | 0 | Common Stock |